Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 65.99% is in line with its 5-year average of 62.19%, around the middle of its 5-year range (52.34%–73.21%).
3.66% above its 12-month average of 63.66%.
Reported quarterly gross margin; no daily interpolation. Q1 FY2027 (2026-06-30): 64.87%.
GROSS MARGIN
65.99%
GROSS MARGIN AVG TTM
63.66%
GROSS MARGIN AVG 3Y
62.49%
GROSS MARGIN AVG 5Y
62.19%
GROSS MARGIN AVG 10Y
60.19%
GROSS MARGIN AVG 15Y
60.63%
GROSS MARGIN AVG 20Y
61.04%
CURRENT VS TTM AVG
+3.66%
CURRENT VS 3Y AVG
+5.60%
CURRENT VS 5Y AVG
+6.12%
CURRENT VS 10Y AVG
+9.63%
CURRENT VS 15Y AVG
+8.83%
CURRENT VS 20Y AVG
+8.10%
SECTOR MEDIAN · HEALTHCARE
41.03%
median of 645 covered companies
CURRENT VS SECTOR MEDIAN
+60.83%
vs the sector median at left
Mesa Laboratories, Inc.
Market Cap
$764.06M
Gross Margin
65.99%
TTM Avg
63.66%
3Y Avg
62.49%
5Y Avg
62.19%
Market Cap
$765.72M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$755.50M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$755.18M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
Market Cap
$781.78M
Gross Margin
98.85%
TTM Avg
98.73%
3Y Avg
-10570.46%
5Y Avg
-10093.61%
Market Cap
$789.07M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
Market Cap
$785.93M
Gross Margin
10.37%
TTM Avg
19.20%
3Y Avg
18.44%
5Y Avg
17.81%
Market Cap
$735.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$731.71M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mesa Laboratories, Inc. (MLAB) | $764.06M | 65.99% | 63.66% | 62.49% | 62.19% |
| Design Therapeutics, Inc. (DSGN)vs › | $765.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Candel Therapeutics, Inc. (CADL)vs › | $755.50M | 0.00% | 0.00% | 25.00% | 50.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.18M | 40.44% | 20.22% | 20.22% | 20.22% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $781.78M | 98.85% | 98.73% | -10570.46% | -10093.61% |
| Geron Corporation (GERN)vs › | $789.07M | 97.42% | 97.90% | 98.95% | -3197.94% |
| AdaptHealth Corp. (AHCO)vs › | $785.93M | 10.37% | 19.20% | 18.44% | 17.81% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $731.71M | 100.00% | 141.50% | 99.31% | 94.19% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $794.93M | 94.30% | 95.84% | 95.72% | 72.44% |
Gross Margin
66.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 64.87% |
| 2026-03-31 | 73.21% |
| 2025-12-31 | 64.18% |
| 2025-09-30 | 61.46% |
| 2025-06-30 | 54.57% |
| 2025-03-31 | 61.82% |
| 2024-12-31 | 63.26% |
| 2024-09-30 | 61.31% |
| 2024-06-30 | 64.03% |
| 2024-03-31 | 62.06% |
| 2023-12-31 | 62.47% |
| 2023-09-30 | 60.39% |
| 2023-06-30 | 61.57% |
| 2023-03-31 | 59.72% |
| 2022-12-31 | 60.36% |
| 2022-09-30 | 61.93% |
| 2022-06-30 | 62.12% |
| 2022-03-31 | 59.63% |
| 2021-12-31 | 52.34% |
| 2021-09-30 | 64.56% |
| 2021-06-30 | 63.61% |
| 2021-03-31 | 65.16% |
| 2020-12-31 | 60.44% |
| 2020-09-30 | 66.81% |
| 2020-06-30 | 67.93% |
| 2020-03-31 | 54.49% |
| 2019-12-31 | 46.76% |
| 2019-09-30 | 54.54% |
| 2019-06-30 | 61.39% |
| 2019-03-31 | 59.04% |
| 2018-12-31 | 58.59% |
| 2018-09-30 | 58.62% |
| 2018-06-30 | 60.02% |
| 2018-03-31 | 59.65% |
| 2017-12-31 | 53.57% |
| 2017-09-30 | 57.65% |
| 2017-06-30 | 55.89% |
| 2017-03-31 | 57.47% |
| 2016-12-31 | 56.78% |
| 2016-09-30 | 56.23% |
| 2016-06-30 | 56.90% |
| 2016-03-31 | 60.44% |
| 2015-12-31 | 61.31% |
| 2015-09-30 | 60.01% |
| 2015-06-30 | 61.36% |
| 2015-03-31 | 62.03% |
| 2014-12-31 | 61.99% |
| 2014-09-30 | 59.99% |
| 2014-06-30 | 59.18% |
| 2014-03-31 | 61.00% |
| 2013-12-31 | 58.75% |
| 2013-09-30 | 59.96% |
| 2013-06-30 | 60.59% |
| 2013-03-31 | 64.11% |
| 2012-12-31 | 61.15% |
| 2012-09-30 | 61.92% |
| 2012-06-30 | 61.13% |
| 2012-03-31 | 53.08% |
| 2011-12-31 | 63.56% |
| 2011-09-30 | 62.15% |
| 2011-06-30 | 60.62% |
| 2011-03-31 | 62.17% |
| 2010-12-31 | 58.02% |
| 2010-09-30 | 58.71% |
| 2010-06-30 | 58.77% |
| 2010-03-31 | 57.83% |
| 2009-12-31 | 62.02% |
| 2009-09-30 | 61.24% |
| 2009-06-30 | 59.94% |
| 2009-03-31 | 64.63% |
| 2008-12-31 | 64.34% |
| 2008-09-30 | 64.20% |
| 2008-06-30 | 63.40% |
| 2008-03-31 | 61.90% |
| 2007-12-31 | 66.91% |
| 2007-09-30 | 67.48% |
| 2007-06-30 | 67.69% |
| 2007-03-31 | 63.68% |
| 2006-12-31 | 60.12% |
| 2006-09-30 | 64.02% |
| 2006-06-30 | 64.97% |
| 2006-03-31 | 65.17% |
| 2005-12-31 | 61.84% |
| 2005-09-30 | 66.26% |
| 2005-06-30 | 63.03% |
| 2005-03-31 | 64.52% |
| 2004-12-31 | 61.86% |
| 2004-09-30 | 62.09% |
| 2004-06-30 | 63.14% |
| 2004-03-31 | 63.19% |
| 2003-12-31 | 61.92% |
| 2003-09-30 | 60.38% |
| 2003-06-30 | 64.22% |
| 2003-03-31 | 61.93% |
| 2002-12-31 | 63.89% |
| 2002-09-30 | 63.88% |
